Compugen Reports Fourth Quarter and Full Year 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
March 4, 2025 10:26 AM ESTRodman & Renshaw analyst Tony Blair reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).
The analyst comments "This morning, before the market opened, Compugen Ltd. (CGEN; Buy) released its business updates for 4Q24. The company reported an ending cash balance of $103.3 million for the quarter, which is expected to provide funding into 2027. CGEN remains on track to initiate a randomized adaptive platform trial in 2Q25 to... More
